# Francesca Mallamaci

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 258 papers | 17,776 citations | 13087 68 h-index | 15716 125 g-index |
| 260 all docs | 260 docs citations | 260 times ranked | 13589 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509. | 0.8 | 9 |
| 2 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. Journal of Nephrology, 2022, 35, 211-221. | 0.9 | 34 |
| 3 | Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982. | 1.0 | 20 |
| 4 | Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42. | 1.4 | 14 |
| 5 | Lung ultrasound-guided dry-weight reduction and echocardiographic changes in clinically euvolemic hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Hellenic Journal of Cardiology, 2022, 64, 1-6. | 0.4 | 3 |
| 6 | Detecting and Treating Lung Congestion with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 757-765. | 2.2 | 5 |
| 7 | Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252. | 1.1 | 15 |
| 8 | Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients. Journal of Nephrology, 2022, , . | 0.9 | 1 |
| 9 | The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. Journal of Hypertension, 2022, 40, 704-711. | 0.3 | 12 |
| 10 | Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076. | 1.4 | 12 |
| 11 | Prognostic values of left ventricular mass index in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2021, 36, 665-672. | 0.4 | 10 |
| 12 | Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097. | 0.3 | 22 |
| 13 | Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study. Internal and Emergency Medicine, 2021, 16, 1803-1811. | 1.0 | 6 |
| 14 | Sleep Apnea as a Cardiorenal Risk Factor in CKD and Renal Transplant Patients. Blood Purification, 2021, 50, 642-648. | 0.9 | 10 |
| 15 | The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clinical Research in Cardiology, 2021, 110, 1073-1082. | 1.5 | 31 |
| 16 | Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346. | 0.4 | 18 |
| 17 | Hypertension in kidney transplantation: a consensus statement of the â€˜hypertension and the kidneyâ€™ working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521. | 0.3 | 16 |
| 18 | A new therapy for sleep apnea?. Journal of Hypertension, 2021, 39, 1098-1101. | 0.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. Drugs, 2021, 81, 1467-1489. | 4.9 | 22 |
| 20 | Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Journal of Hypertension, 2021, 39, 1444-1452. | 0.3 | 4 |
| 21 | A randomized multicenter trial on a lung ultrasoundâ€“guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney International, 2021, 100, 1325-1333. | 2.6 | 45 |
| 22 | Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652. | 1.1 | 18 |
| 23 | Can the assessment of ultrasound lung water in haemodialysis patients be simplified?. Nephrology Dialysis Transplantation, 2021, 36, 2321-2326. | 0.4 | 15 |
| 24 | Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69. | 0.3 | 49 |
| 25 | Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 333-340. | 0.3 | 46 |
| 26 | Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. Journal of Hypertension, 2021, 39, 408-416. | 0.3 | 25 |
| 27 | Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23. | 0.4 | 11 |
| 28 | Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2020, 35, 878-887. | 0.4 | 32 |
| 29 | Lung ultrasound to detect and monitor pulmonary congestion in patients with acute kidney injury in nephrology wards: a pilot study. Journal of Nephrology, 2020, 33, 335-341. | 0.9 | 7 |
| 30 | Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. Journal of Nephrology, 2020, 33, 583-590. | 0.9 | 4 |
| 31 | Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308. | 1.3 | 177 |
| 32 | FGF23 and the PTH response to paricalcitol in chronic kidney disease. European Journal of Clinical Investigation, 2020, 50, e13196. | 1.7 | 8 |
| 33 | Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. Journal of Clinical Medicine, 2020, 9, 2359. | 1.0 | 123 |
| 34 | Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of Hypertension, 2020, 38, 1849-1856. | 0.3 | 15 |
| 35 | Long-Term Changes in Sleep Disordered Breathing in Renal Transplant Patients: Relevance of the BMI. Journal of Clinical Medicine, 2020, 9, 1739. | 1.0 | 5 |
| 36 | Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial. Nephrology Dialysis Transplantation, 2020, 35, ii18-ii22. | 0.4 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Sleepâ€Disordered Breathing and 24â€Hour Ambulatory Blood Pressure Monitoring in Renal Transplant Patients: Longitudinal Study. Journal of the American Heart Association, 2020, 9, e016237. | 1.6 | 8 |
| 38 | The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029. | 2.2 | 69 |
| 39 | Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. Journal of Nephrology, 2020, 33, 1289-1300. | 0.9 | 7 |
| 40 | Thyroid Dysfunction and Cardiovascular Disease in Chronic Kidney Disease. , 2020, , 327-338. | | 0 |
| 41 | Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 1542-1548. | 0.4 | 21 |
| 42 | Physical functioning and mortality in very old patients on dialysis. Archives of Gerontology and Geriatrics, 2019, 85, 103918. | 1.4 | 2 |
| 43 | Lung Ultrasound-Guided Dry-Weight Reduction in Hemodialysis Patients Does Not Affect Short-Term Blood Pressure Variability. American Journal of Hypertension, 2019, 32, 786-795. | 1.0 | 12 |
| 44 | Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study. Journal of Clinical Medicine, 2019, 8, 523. | 1.0 | 14 |
| 45 | Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350. | 2.1 | 17 |
| 46 | SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230. | 0.4 | 147 |
| 47 | Urine chloride self-measurement to monitor sodium chloride intake in patients with chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1162-1168. | 1.4 | 8 |
| 48 | Sympathetic neural overdrive in congestive heart failure and its correlates. Journal of Hypertension, 2019, 37, 1746-1756. | 0.3 | 34 |
| 49 | Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients. Journal of Hypertension, 2019, 37, 1359-1365. | 0.3 | 10 |
| 50 | Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 233-240. | 2.2 | 39 |
| 51 | Long-term blood pressure monitoring by office and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study. Nephrology Dialysis Transplantation, 2019, 34, 1558-1564. | 0.4 | 19 |
| 52 | Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial. Nephrology Dialysis Transplantation, 2019, 34, 819-824. | 0.4 | 6 |
| 53 | Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension, 2018, 71, 585-591. | 1.3 | 149 |
| 54 | Neuropeptide Y and chronic kidney disease progression: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 1805-1812. | 0.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The overdriven glomerulus as a cardiovascular risk factor. Kidney International, 2018, 93, 13-15. | 2.6 | 8 |
| 56 | Uric acid in chronic kidney disease: the quest for causality continues. Nephrology Dialysis Transplantation, 2018, 33, 193-195. | 0.4 | 16 |
| 57 | Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Nephrology Dialysis Transplantation, 2018, 33, 1764-1769. | 0.4 | 8 |
| 58 | The sirtuin1 gene associates with left ventricular myocardial hypertrophy and remodeling in two chronic kidney disease cohorts. Journal of Hypertension, 2018, 36, 1705-1711. | 0.3 | 6 |
| 59 | Pulse Wave Velocity and Prognosis in End-Stage Kidney Disease. Hypertension, 2018, 71, 1126-1132. | 1.3 | 28 |
| 60 | Validation of echocardiographic criteria for the clinical diagnosis of heart failure in chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 653-660. | 0.4 | 8 |
| 61 | Office, standardized and 24-h ambulatory blood pressure and renal function loss in renal transplant patients. Journal of Hypertension, 2018, 36, 119-125. | 0.3 | 23 |
| 62 | Short-term blood pressure variability in nondialysis chronic kidney disease patients. Journal of Hypertension, 2018, 36, 2398-2405. | 0.3 | 26 |
| 63 | The dominant prognostic value of physical functioning among quality of life domains in end-stage kidney disease. Nephrology Dialysis Transplantation, 2018, 35, 170-175. | 0.4 | 4 |
| 64 | Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial. BMC Geriatrics, 2018, 18, 248. | 1.1 | 59 |
| 65 | FP720SLEEP DISORDERED BREATHING IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY. Nephrology Dialysis Transplantation, 2018, 33, i288-i288. | 0.4 | 1 |
| 66 | Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients. Kidney International Reports, 2018, 3, 1100-1109. | 0.4 | 11 |
| 67 | Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1432-1434. | 2.2 | 17 |
| 68 | Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. Hypertension, 2018, 72, 483-491. | 1.3 | 79 |
| 69 | Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Associationâ€“European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation, 2017, 32, 620-640. | 0.4 | 133 |
| 70 | The systemic nature of CKD. Nature Reviews Nephrology, 2017, 13, 344-358. | 4.1 | 265 |
| 71 | Intact FGF23 and Î±â€klotho during acute inflammation/sepsis in CKD patients. European Journal of Clinical Investigation, 2017, 47, 470-472. | 1.7 | 5 |
| 72 | Chronic Fluid Overload and Mortality in ESRD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2491-2497. | 3.0 | 286 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676. | 0.3 | 56 |
| 74 | Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2017, 28, 1259-1268. | 3.0 | 272 |
| 75 | Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, . | 1.6 | 64 |
| 76 | Reappraisal in two European cohorts ofÂtheÂprognostic power of left ventricular massÂindexÂin chronic kidney failure. Kidney International, 2017, 91, 704-710. | 2.6 | 13 |
| 77 | Clinical News. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 368-371. | 0.2 | 0 |
| 78 | Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. Nephrology Dialysis Transplantation, 2017, 32, 1351-1356. | 0.4 | 16 |
| 79 | Optimizing hypertension management in renal transplantation. Journal of Hypertension, 2017, 35, 2335-2338. | 0.3 | 5 |
| 80 | Optimizing hypertension management in renal transplantation: a call to action. Nephrology Dialysis Transplantation, 2017, 32, 1959-1962. | 0.4 | 14 |
| 81 | Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-7. | 1.9 | 7 |
| 82 | Vitamin D and methylarginines in chronic kidney disease (CKD). PLoS ONE, 2017, 12, e0185449. | 1.1 | 3 |
| 83 | Arterial Stiffness as a Cardiovascular Risk Factor in Stage 5D Chronic Kidney Disease Patients: An Age Affair. American Journal of Nephrology, 2017, 45, 69-71. | 1.4 | 2 |
| 84 | Moderator's view: Phosphate binders in chronic kidney disease patients: a clear â€˜Noâ€™ at the moment, but stay tuned. Nephrology Dialysis Transplantation, 2016, 31, gfv404. | 0.4 | 6 |
| 85 | Nocturnal Hypertension and Altered Nightâ€“Day BP Profile and Atherosclerosis in Renal Transplant Patients. Transplantation, 2016, 100, 2211-2218. | 0.5 | 27 |
| 86 | A polymorphism in a major antioxidant gene (Kelch-like ECH-associated protein 1) predicts incident cardiovascular events in chronic kidney disease patients. Journal of Hypertension, 2016, 34, 928-934. | 0.3 | 12 |
| 87 | Intact FGF23 and Î±â€klotho during acute inflammation/sepsis in CKD patients. European Journal of Clinical Investigation, 2016, 46, 234-241. | 1.7 | 28 |
| 88 | Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes and Endocrinology,the, 2016, 4, 360-373. | 5.5 | 78 |
| 89 | Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101. | 1.3 | 63 |
| 90 | Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110. | 1.3 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. Nephrology Dialysis Transplantation, 2016, 31, 1982-1988. | 0.4 | 60 |
| 92 | The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2005-2011. | 2.2 | 124 |
| 93 | Respiratory muscle impairment in dialysis patients: can minimal dose of exercise limit the damage? A Preliminary study in a sample of patients enrolled in the EXCITE trial. Journal of Nephrology, 2016, 29, 863-869. | 0.9 | 20 |
| 94 | Physical exercise in haemodialysis patients: time to start. Nephrology Dialysis Transplantation, 2016, 31, 1196-1198. | 0.4 | 6 |
| 95 | Highlights of the 2015 ERA-EDTA congress: chronic kidney disease, hypertension. Nephrology Dialysis Transplantation, 2016, 31, 1044-1046. | 0.4 | 7 |
| 96 | Cocoa Flavanols. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 9-11. | 2.2 | 1 |
| 97 | Subclinical pulmonary congestion is prevalent in nephrotic syndrome. Kidney International, 2016, 89, 421-428. | 2.6 | 21 |
| 98 | Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. European Journal of Clinical Investigation, 2015, 45, 1077-1086. | 1.7 | 8 |
| 99 | Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease. Seminars in Dialysis, 2015, 28, 587-593. | 0.7 | 4 |
| 100 | Association between Resistin Levels and All-Cause and Cardiovascular Mortality: A New Study and a Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0120419. | 1.1 | 69 |
| 101 | Epidemiology of CKD Regression in Patients under Nephrology Care. PLoS ONE, 2015, 10, e0140138. | 1.1 | 27 |
| 102 | A Longitudinal Study of Inflammation, CKD-Mineral Bone Disorder, and Carotid Atherosclerosis after Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 471-479. | 2.2 | 24 |
| 103 | Moderator's view: Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1443-1448. | 0.4 | 30 |
| 104 | The Role of Deconditioning in the End-Stage Renal Disease Myopathy: Physical Exercise Improves Altered Resting Muscle Oxygen Consumption. American Journal of Nephrology, 2015, 41, 329-336. | 1.4 | 41 |
| 105 | Should we extend the application of more frequent dialysis schedules? A 'yes' and a hopeful 'no'. Nephrology Dialysis Transplantation, 2015, 30, 29-32. | 0.4 | 2 |
| 106 | Association of IL-6 and a Functional Polymorphism in the IL-6 Gene with Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 232-240. | 2.2 | 64 |
| 107 | High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2â€“4 chronic kidney disease. Kidney International, 2015, 88, 130-136. | 2.6 | 31 |
| 108 | Norepinephrine, left ventricular disorders and volume excess in ESRD. Journal of Nephrology, 2015, 28, 729-737. | 0.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1560-1567. | 2.2 | 11 |
| 110 | Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. Hypertension, 2015, 66, 3-9. | 1.3 | 23 |
| 111 | Immunity in arterial hypertension: associations or causalities?. Nephrology Dialysis Transplantation, 2015, 30, 1959-1964. | 0.4 | 22 |
| 112 | The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598. | 6.3 | 147 |
| 113 | A Genetic Marker of Uric Acid Level, Carotid Atherosclerosis, and Arterial Stiffness: A Family-Based Study. American Journal of Kidney Diseases, 2015, 65, 294-302. | 2.1 | 27 |
| 114 | Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 935-944. | 3.0 | 21 |
| 115 | Left ventricular hypertrophy in chronic kidney disease. , 2015, , 837-852. | | 6 |
| 116 | Association of a Polymorphism in a Gene Encoding a Urate Transporter with CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1059-1065. | 2.2 | 51 |
| 117 | Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension, 2014, 64, 1005-1011. | 1.3 | 106 |
| 118 | Ramipril Lowers Plasma FGF-23 in Patients with Diabetic Nephropathy. American Journal of Nephrology, 2014, 40, 208-214. | 1.4 | 20 |
| 119 | Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality?. Kidney International, 2014, 86, 469-471. | 2.6 | 15 |
| 120 | Chronic Kidney Disease (CKD) as a Systemic Disease: Whole Body Autoregulation and Inter-Organ Cross-Talk. Kidney and Blood Pressure Research, 2014, 39, 134-141. | 0.9 | 6 |
| 121 | Fitness for Entering a Simple Exercise Program and Mortality: A Study Corollary to the Exercise Introduction to Enhance Performance in Dialysis (Excite) Trial. Kidney and Blood Pressure Research, 2014, 39, 197-204. | 0.9 | 17 |
| 122 | Physical Performance and Clinical Outcomes in Dialysis Patients: A Secondary Analysis of the Excite Trial. Kidney and Blood Pressure Research, 2014, 39, 205-211. | 0.9 | 72 |
| 123 | Joint effect of insulin signaling genes on all-cause mortality. Atherosclerosis, 2014, 237, 639-644. | 0.4 | 7 |
| 124 | Cardiovascular protection by Â-blockade in hypertensive haemodialysis patients: the Hypertension in Haemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial. Nephrology Dialysis Transplantation, 2014, 29, 483-485. | 0.4 | 6 |
| 125 | Fluid overload and post-dialysis hypertension. Nature Reviews Nephrology, 2014, 10, 623-624. | 4.1 | 1 |
| 126 | Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet, The, 2014, 383, 1831-1843. | 6.3 | 341 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Snoring Amplifies the Risk of Heart Failure and Mortality in Dialysis Patients. American Journal of Nephrology, 2014, 39, 536-542. | 1.4 | 15 |
| 128 | Obesity and nephrology: results of a knowledge and practice pattern survey. Nephrology Dialysis Transplantation, 2013, 28, iv99-iv104. | 0.4 | 33 |
| 129 | Uric Acid, Hypertension, and Cardiovascular and Renal Complications. Current Hypertension Reports, 2013, 15, 531-537. | 1.5 | 45 |
| 130 | Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. Atherosclerosis, 2013, 226, 140-145. | 0.4 | 23 |
| 131 | Value of Troponin T as a Screening Test for Left Ventricular Hypertrophy in CKD. American Journal of Kidney Diseases, 2013, 61, 689-691. | 2.1 | 2 |
| 132 | Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622. | 2.1 | 119 |
| 133 | Longitudinal Analysis of Vascular Function and Biomarkers of Metabolic Bone Disorders before and after Renal Transplantation. American Journal of Nephrology, 2013, 37, 126-134. | 1.4 | 39 |
| 134 | FGF23: A Mature Renal and Cardiovascular Risk Factor?. Blood Purification, 2013, 36, 52-57. | 0.9 | 24 |
| 135 | Obesity and CKD progression: hard facts on fat CKD patients. Nephrology Dialysis Transplantation, 2013, 28, iv105-iv108. | 0.4 | 36 |
| 136 | The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrology Dialysis Transplantation, 2013, 28, 19-23. | 0.4 | 15 |
| 137 | Salt and the heart in chronic kidney disease: an atrial connection. Nephrology Dialysis Transplantation, 2013, 28, 2210-2211. | 0.4 | 5 |
| 138 | Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrology Dialysis Transplantation, 2013, 28, iv181-iv187. | 0.4 | 30 |
| 139 | Lung congestion as a hidden threat in end-stage kidney disease: a call to action. Nephrology Dialysis Transplantation, 2013, 28, 2657-2660. | 0.4 | 12 |
| 140 | Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD. Journal of the American Society of Nephrology: JASN, 2013, 24, 639-646. | 3.0 | 221 |
| 141 | Asymptomatic Pulmonary Congestion and Physical Functioning in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1343-1348. | 2.2 | 50 |
| 142 | Lung Congestion as a Risk Factor in End-Stage Renal Disease. Blood Purification, 2013, 36, 184-191. | 0.9 | 32 |
| 143 | Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. Kidney International, 2013, 84, 381-389. | 2.6 | 65 |
| 144 | The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. Nephrology Dialysis Transplantation, 2012, 27, iv58-iv62. | 0.4 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Assessment of obesity in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2012, 21, 641-646. | 1.0 | 56 |
| 146 | Thyroid Function and Clinical Outcomes in Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 12-14. | 2.2 | 22 |
| 147 | Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. Nephrology Dialysis Transplantation, 2012, 27, 661-666. | 0.4 | 9 |
| 148 | Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. Nephrology Dialysis Transplantation, 2012, 27, 2440-2445. | 0.4 | 3 |
| 149 | eNOS and Caveolin-1 Gene Polymorphisms Interaction and Intima Media Thickness: A Proof of Concept Study in ESRD Patients. American Journal of Hypertension, 2012, 25, 103-108. | 1.0 | 15 |
| 150 | The burden of physical inactivity in chronic kidney disease: is there an exit strategy?. Nephrology Dialysis Transplantation, 2012, 27, 2143-2145. | 0.4 | 24 |
| 151 | Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. BMC Nephrology, 2012, 13, 134. | 0.8 | 23 |
| 152 | Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. American Journal of Kidney Diseases, 2012, 59, 177-185. | 2.1 | 128 |
| 153 | Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. Journal of Nephrology, 2012, 25, 1016-1022. | 0.9 | 17 |
| 154 | Heart rate, age and the risk of progression to kidney failure in patients with CKD. Journal of Nephrology, 2012, 25, 20-27. | 0.9 | 9 |
| 155 | The MAURO study: baseline characteristics and compliance with guidelines targets. Journal of Nephrology, 2012, 25, 1081-1090. | 0.9 | 18 |
| 156 | The ENPP1 Q121 Variant Predicts Major Cardiovascular Events in High-Risk Individuals. Diabetes, 2011, 60, 1000-1007. | 0.3 | 37 |
| 157 | Adiponectin and Leptin in Chronic Kidney Disease: Causal Factors or Mere Risk Markers?. , 2011, 21, 87-91. | | 41 |
| 158 | Aging and Left Ventricular Mass and Function in People with Endâ€Stage Renal Disease. Journal of the American Geriatrics Society, 2011, 59, 1636-1641. | 1.3 | 7 |
| 159 | Obesity and the Epidemiology and Prevention of Kidney Disease: Waist Circumference Versus Body Mass Index. American Journal of Kidney Diseases, 2011, 58, 157-159. | 2.1 | 14 |
| 160 | Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1714-1721. | 2.2 | 98 |
| 161 | Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1923-1930. | 3.0 | 190 |
| 162 | Comment accompanying: obstructive sleep apnoea: a stand-alone risk factor for chronic kidney disease by Chou Yu-Ting. Nephrology Dialysis Transplantation, 2011, 26, 2072-2074. | 0.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128. | 3.0 | 119 |
| 164 | Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events.. Journal of Nephrology, 2011, 24, 465-473. | 0.9 | 31 |
| 165 | Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. Journal of Hypertension, 2010, 28, 1745-1751. | 0.3 | 9 |
| 166 | Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. Journal of Bone and Mineral Research, 2010, 25, 313-319. | 3.1 | 59 |
| 167 | Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89. | 1.3 | 70 |
| 168 | Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients. Nephron Clinical Practice, 2010, 114, c74-c80. | 2.3 | 5 |
| 169 | Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 77, 225-231. | 2.6 | 60 |
| 170 | Detection of Pulmonary Congestion by Chest Ultrasound in Dialysis Patients. JACC: Cardiovascular Imaging, 2010, 3, 586-594. | 2.3 | 232 |
| 171 | Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. Journal of Hypertension, 2010, 28, 2468-2474. | 0.3 | 14 |
| 172 | Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II. , 2010, , 299-308. | | 0 |
| 173 | Biomarkers of Left Atrial Volume. Hypertension, 2009, 54, 818-824. | 1.3 | 49 |
| 174 | Vitamin D levels and patient outcome in chronic kidney disease. Kidney International, 2009, 75, 88-95. | 2.6 | 384 |
| 175 | Clinical Implications of Elevated Asymmetric Dimethylarginine in Chronic Kidney Disease and End-Stage Renal Disease. , 2009, 19, 25-28. | | 9 |
| 176 | Thyroid, Renal Function, and Cardiac Outcome. , 2009, , 191-201. | | 1 |
| 177 | Urotensin II and Cardiomyopathy in End-Stage Renal Disease. Hypertension, 2008, 51, 326-333. | 1.3 | 19 |
| 178 | Rate of Atherosclerotic Plaque Formation Predicts Cardiovascular Events in ESRD. Journal of the American Society of Nephrology: JASN, 2008, 19, 757-763. | 3.0 | 41 |
| 179 | Obesity, diabetes, adiponectin and the kidney: a podocyte affair. Nephrology Dialysis Transplantation, 2008, 23, 3767-3770. | 0.4 | 17 |
| 180 | Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. Journal of Hypertension, 2008, 26, 1875-1882. | 0.3 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Urotensin II: a cardiovascular and renal update. Current Opinion in Nephrology and Hypertension, 2008, 17, 199-204. | 1.0 | 24 |
| 182 | The MAURO study: multiple intervention and audit in renal diseases to optimize care. Journal of Nephrology, 2008, 21, 20-2. | 0.9 | 7 |
| 183 | Comparison of the Captopril and the Saline Infusion Test for Excluding Aldosterone-Producing Adenoma. Hypertension, 2007, 50, 424-431. | 1.3 | 142 |
| 184 | Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrology Dialysis Transplantation, 2007, 22, 3521-3526. | 0.4 | 32 |
| 185 | Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease: A Prospective Cohort Study. Journal of the American Society of Nephrology: JASN, 2007, 18, 1316-1322. | 3.0 | 78 |
| 186 | Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. Journal of Hypertension, 2007, 25, 1433-1442. | 0.3 | 90 |
| 187 | An Additive Effect of Endothelial Nitric Oxide Synthase Gene Polymorphisms Contributes to the Severity of Atherosclerosis in Patients on Dialysis. American Journal of Hypertension, 2007, 20, 758-763. | 1.0 | 9 |
| 188 | Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First. Seminars in Dialysis, 2007, 20, 405-408. | 0.7 | 1 |
| 189 | CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: It Is Important to Lower Homocysteine in Dialysis Patients. Seminars in Dialysis, 2007, 20, 530-533. | 0.7 | 8 |
| 190 | Neuropeptide Y and Markers of Osteoblast Activity in Dialysis Patients: A Cross-Sectional Study. American Journal of Kidney Diseases, 2007, 50, 1001-1008. | 2.1 | 9 |
| 191 | A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. Journal of the American College of Cardiology, 2006, 48, 2293-2300. | 1.2 | 1,236 |
| 192 | Urotensin II and Biomarkers of Endothelial Activation and Atherosclerosis in End-Stage Renal Disease. American Journal of Hypertension, 2006, 19, 505-510. | 1.0 | 21 |
| 193 | Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. Journal of Hypertension, 2006, 24, 2039-2046. | 0.3 | 55 |
| 194 | Left atrial volume in end-stage renal disease: a prospective cohort study. Journal of Hypertension, 2006, 24, 1173-1180. | 0.3 | 90 |
| 195 | Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD). European Journal of Clinical Pharmacology, 2006, 62, 131-135. | 0.8 | 8 |
| 196 | Mendelian Randomization: A New Approach to Studying Epidemiology in ESRD. American Journal of Kidney Diseases, 2006, 47, 332-341. | 2.1 | 43 |
| 197 | The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease. Nephrology Dialysis Transplantation, 2006, 21, 1921-1926. | 0.4 | 18 |
| 198 | Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2006, 22, 538-544. | 0.4 | 94 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2006, 17, S169-S173. | 3.0 | 101 |
| 200 | Uric Acid and Endothelial Dysfunction in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, 1466-1471. | 3.0 | 202 |
| 201 | Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, S64-S68. | 3.0 | 39 |
| 202 | Left Ventricular Systolic Function Monitoring in Asymptomatic Dialysis Patients: A Prospective Cohort Study. Journal of the American Society of Nephrology: JASN, 2006, 17, 1460-1465. | 3.0 | 48 |
| 203 | The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. Journal of Hypertension, 2005, 23, 1825-1830. | 0.3 | 27 |
| 204 | Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney International, 2005, 67, 2330-2337. | 2.6 | 116 |
| 205 | Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney International, 2005, 68, 1294-1302. | 2.6 | 114 |
| 206 | Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. American Journal of Kidney Diseases, 2005, 45, 702-707. | 2.1 | 42 |
| 207 | Clinical Epidemiology of Major Nontraditional Risk Factors in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2005, 25, 84-87. | 1.1 | 29 |
| 208 | Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD: Searching for the Best Risk Marker by Multivariate Modeling. Journal of the American Society of Nephrology: JASN, 2005, 16, S83-S88. | 3.0 | 217 |
| 209 | Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach. Journal of the American Society of Nephrology: JASN, 2005, 16, 2449-2455. | 3.0 | 352 |
| 210 | Low Triiodothyronine: A New Facet of Inflammation in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2789-2795. | 3.0 | 132 |
| 211 | Predictors of Cardiovascular Death in ESRD. Seminars in Nephrology, 2005, 25, 358-362. | 0.6 | 76 |
| 212 | Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. , 2005, 15, 125-130. | | 45 |
| 213 | Atherosclerosis and the Glu298Asp Polymorphism of the eNOS Gene in White Patients With End-Stage Renal Disease. American Journal of Hypertension, 2005, 18, 1549-1555. | 1.0 | 14 |
| 214 | Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. Journal of Nephrology, 2005, 18, 727-32. | 0.9 | 19 |
| 215 | Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1029-1037. | 3.0 | 180 |
| 216 | Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 435-441. | 3.0 | 93 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Novel Cardiovascular Risk Factors in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 77S-80. | 3.0 | 120 |
| 218 | Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, v67-v72. | 0.4 | 62 |
| 219 | Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney International, 2004, 65, 1492-1498. | 2.6 | 299 |
| 220 | HYPERTENSION IN HEMODIALYSIS PATIENTS: Cardiac Consequences of Hypertension in Hemodialysis Patients. Seminars in Dialysis, 2004, 17, 299-303. | 0.7 | 38 |
| 221 | Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 479-484. | 2.1 | 47 |
| 222 | Leptin and biochemical markers of bone turnover in dialysis patients. Journal of Nephrology, 2004, 17, 253-60. | 0.9 | 16 |
| 223 | Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney International, 2003, 64, 579-584. | 2.6 | 22 |
| 224 | Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney International, 2003, 63, S98-S102. | 2.6 | 110 |
| 225 | Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease. Kidney International, 2003, 63, S65-S68. | 2.6 | 72 |
| 226 | Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney International, 2003, 63, S105-S110. | 2.6 | 168 |
| 227 | Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease. Hypertension, 2003, 41, 88-92. | 1.3 | 27 |
| 228 | Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 2611-2617. | 3.0 | 48 |
| 229 | Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. Journal of Hypertension, 2003, 21, 1355-1362. | 0.3 | 23 |
| 230 | Inflammation and Atherosclerosis in End-Stage Renal Disease. Blood Purification, 2003, 21, 29-36. | 0.9 | 76 |
| 231 | Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. Circulation, 2002, 105, 1354-1359. | 1.6 | 485 |
| 232 | Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. Hypertension, 2002, 40, 41-46. | 1.3 | 123 |
| 233 | Atherosclerotic Renal Artery Stenosis: Epidemiology, Cardiovascular Outcomes, and Clinical Prediction Rules. Journal of the American Society of Nephrology: JASN, 2002, 13, S179-S183. | 3.0 | 379 |
| 234 | Nocturnal Hypoxemia: A Neglected Cardiovascular Risk Factor in End-Stage Renal Disease?. Blood Purification, 2002, 20, 120-123. | 0.9 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 68-75. | 2.1 | 144 |
| 236 | Low parathyroid hormone and pentosidine in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 810-815. | 2.1 | 20 |
| 237 | Hypertension as a cardiovascular risk factor in end-stage renal failure. Current Hypertension Reports, 2002, 4, 381-386. | 1.5 | 18 |
| 238 | Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney International, 2002, 61, 609-614. | 2.6 | 247 |
| 239 | Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney International, 2002, 62, 339-345. | 2.6 | 194 |
| 240 | Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?. Kidney International, 2002, 62, 1791-1798. | 2.6 | 175 |
| 241 | Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney International, 2002, 62, 1884-1890. | 2.6 | 66 |
| 242 | Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 134-141. | 3.0 | 560 |
| 243 | Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 490-496. | 3.0 | 235 |
| 244 | Nocturnal Hypoxemia Predicts Incident Cardiovascular Complications in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 729-733. | 3.0 | 122 |
| 245 | Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, The, 2001, 358, 2113-2117. | 6.3 | 993 |
| 246 | Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. Journal of Hypertension, 2001, 19, 287-293. | 0.3 | 52 |
| 247 | Longâ€term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 1459-1464. | 0.4 | 181 |
| 248 | Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney International, 2001, 59, 1559-1566. | 2.6 | 145 |
| 249 | Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. Nephrology Dialysis Transplantation, 2001, 16, 70-77. | 0.4 | 121 |
| 250 | Prognostic Value of Ultrasonographic Measurement of Carotid Intima Media Thickness in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 2458-2464. | 3.0 | 166 |
| 251 | Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 2768-2774. | 3.0 | 246 |
| 252 | Sleep Apnea in Renal Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 2854-2859. | 3.0 | 72 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Cardiac Natriuretic Peptides Are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2001, 12, 1508-1515. | 3.0 | 270 |
| 254 | AGEs and carbonyl stress: potential pathogenetic factors of longâ€term uraemic complications. Nephrology Dialysis Transplantation, 2000, 15, 7-11. | 0.4 | 41 |
| 255 | Inflammation is associated with carotid atherosclerosis in dialysis patients. Journal of Hypertension, 2000, 18, 1207-1213. | 0.3 | 179 |
| 256 | Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. American Journal of Kidney Diseases, 2000, 36, 945-952. | 2.1 | 56 |
| 257 | Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. Journal of Hypertension, 1999, 17, 1751-1758. | 0.3 | 92 |
| 258 | Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney International, 1998, 53, 1078-1084. | 2.6 | 120 |